ARTICLE | Clinical News
Cyclacel gives seliciclib update
August 29, 2008 1:53 AM UTC
Cyclacel (NASDAQ:CYCC) said seliciclib would "probably not" demonstrate an improvement in progression-free survival, the primary endpoint, in the Phase IIb APPRAISE trial to treat non-small cell lung ...